{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=3", "query": { "intervention": "pomalidomide", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 204, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T16:40:59.487Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05020236", "title": "A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 893, "start_date": "2021-10-04", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 26, "location_summary": "Clovis, California • Fresno, California • Fort Collins, Colorado + 17 more", "locations": [ { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05020236" }, { "nct_id": "NCT04191616", "title": "Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed or Refractory Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 54, "start_date": "2020-08-06", "completion_date": "2024-10-01", "has_results": true, "last_update_posted_date": "2025-09-04", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago Ridge", "state": "Illinois" }, { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191616" }, { "nct_id": "NCT05922501", "title": "Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsed Cancer", "Refractory Multiple Myeloma", "Multiple Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Belantamab mafodotin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2024-05-31", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05922501" }, { "nct_id": "NCT03151811", "title": "A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Melflufen", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncopeptides AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 495, "start_date": "2017-06-12", "completion_date": "2023-02-03", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 14, "location_summary": "Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orange City", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03151811" }, { "nct_id": "NCT04850599", "title": "Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Isatuximab", "type": "BIOLOGICAL" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-06-14", "completion_date": "2029-02-21", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT04850599" }, { "nct_id": "NCT05556616", "title": "A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Modakafusp alfa", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-01-12", "completion_date": "2024-06-04", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 14, "location_summary": "Sacramento, California • San Diego, California • Iowa City, Iowa + 8 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT05556616" }, { "nct_id": "NCT03257631", "title": "A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Central Nervous System Neoplasms", "Medulloblastoma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 53, "start_date": "2017-09-18", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-04-16", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 6, "location_summary": "Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03257631" }, { "nct_id": "NCT01835561", "title": "Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Pharmacology, Healthy Volunteer Study" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "MALE", "summary": "18 Years to 70 Years · Male only" }, "enrollment_count": 32, "start_date": "2013-03-01", "completion_date": "2014-08-21", "has_results": false, "last_update_posted_date": "2019-11-12", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 2, "location_summary": "Orlando, Florida • Minneapolis, Minnesota", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835561" }, { "nct_id": "NCT02289222", "title": "1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "MK-3475", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ashraf Badros", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-12-30", "completion_date": "2017-08-07", "has_results": true, "last_update_posted_date": "2019-11-05", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289222" }, { "nct_id": "NCT02990338", "title": "Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Isatuximab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 307, "start_date": "2016-12-22", "completion_date": "2023-11-01", "has_results": true, "last_update_posted_date": "2025-01-17", "last_synced_at": "2026-10-21T16:40:59.487Z", "location_count": 2, "location_summary": "Plantation, Florida • Boston, Massachusetts", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02990338" } ] }